High dose flu shot no better than standard one in high risk CVD patients: JAMA

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-12-07 05:45 GMT | Update On 2020-12-07 09:12 GMT

Researchers have observed in a new study that in patients with high-risk cardiovascular disease, high-dose trivalent influenza vaccine, compared with the standard-dose quadrivalent vaccine, did not significantly reduce all-cause mortality or hospitalizations for cardiac or pulmonary causes.High-dose influenza vaccine is not superior to standard-dose vaccine in high-risk adults with cardiovascular disease (CVD).

This study is published in the JAMA Network.

Influenza is temporally associated with cardiopulmonary morbidity and mortality among those with cardiovascular disease who may mount a less vigorous immune response to vaccination. Higher influenza vaccine dose has been associated with reduced risk of influenza illness.

The Centers for Disease Control and Prevention recommends annual influenza vaccination in those 6 months or older and professional cardiovascular societies emphasize annual influenza vaccination in patients with cardiovascular conditions, without specific guidance regarding the choice of vaccine formulation.

Hence, Orly Vardeny and associates from the Department of Medicine, University of Minnesota, Minneapolis VA Health Care System, Minneapolis, Minnesota conducted this study to evaluate whether high-dose trivalent influenza vaccine compared with standard-dose quadrivalent influenza vaccine would reduce all-cause death or cardiopulmonary hospitalization in high-risk patients with cardiovascular disease.

A total of 5260 participants were randomly assigned to receive high-dose trivalent (n = 2630) or standard-dose quadrivalent (n = 2630) inactivated influenza vaccine and could be revaccinated for up to 3 seasons. The primary outcome was the time to the composite of all-cause death or cardiopulmonary hospitalization during each enrolling season.

Among the participants, 7154 total vaccinations were administered and 5226 (99.4%) participants completed the trial. In the high-dose trivalent vaccine group, there were 975 primary outcome events (883 hospitalizations for cardiovascular or pulmonary causes and 92 deaths from any cause) among 884 participants during 3577 participant-seasons (event rate, 45 per 100 patient-years), whereas in the standard-dose quadrivalent vaccine group, there were 924 primary outcome events (846 hospitalizations for cardiovascular or pulmonary causes and 78 deaths from any cause) among 837 participants during 3577 participant-seasons.

The authors noted that in the high-dose vs standard-dose groups, vaccine-related adverse reactions occurred in 1449 (40.5%) vs 1229 (34.4%) participants and severe adverse reactions occurred in 55 (2.1%) vs 44 (1.7%) participants.

Therefore, they concluded that "in patients with high-risk cardiovascular disease, high-dose trivalent inactivated influenza vaccine, compared with standard-dose quadrivalent inactivated influenza vaccine did not significantly reduce all-cause mortality or cardiopulmonary hospitalizations. Influenza vaccination remains strongly recommended in this population."

For further reference log on to:

JAMA. Published online December 4, 2020. doi:10.1001/jama.2020.23649

Article Source : JAMA Network

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

High dose flu shot no better than standard one in high risk CVD patients: JAMA

Similar News

The Prediabetes Show - Episode 2: Catching It Before Progression-A Window of Opportunity?

PCV20 Launch in India: A Single Dose, Science-Driven Approach for Pneumococcal Disease Control

JAMA Study Questions Routine Prophylactic Antibiotics use for Upper-GI Bleeding in Cirrhosis

Updated Clinical Guidelines on Pharmacotherapy for Obesity Management: CMAJ

FDA Grants Priority Review to Gepotidacin for Gonorrhea Treatment

Laser therapy enhances treatment of fungus resistant to conventional medication, reports research

Heart Failure in Women: Updates from the National Consensus on Bisoprolol

Vitamin D Deficiency Linked to Multiple Diabetic Complications: Study